Pharmaceuticals

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

A new report reveals a major shift in hospital spending, with tech and infrastructure costs now rising faster than drugs for the first time in a decade.

Amid a relentless outbreak, Brazil launches a massive pilot program for the IXCHIQ® vaccine, a critical test for public health and global preparedness.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

Bolstered by a massive capital infusion and strong investor demand, Vaxcyte is set to accelerate its broad-spectrum vaccine pipeline against market leaders.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

Amid rising drug price scrutiny, Red Nucleus acquires an AI-powered consultancy to revolutionize how biopharma proves the value of new medicines.

Beyond M&A, ACROBiosystems' bioSeedin summit redefines growth, connecting global capital with biotech innovation in a new era of strategic partnerships.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

Devonian appoints veteran CFO Dennis Turpin and corrects stock options, signaling a strategic shift as it aims to overcome financial hurdles and advance its pipeline.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

Ensem Therapeutics expands its global trial for ETX-636, a next-gen cancer drug designed to avoid common toxicities, into China's vast patient market.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

A life-changing treatment for a rare kidney disease is now easily accessible in France, ending a long wait for patients and bolstering a French pharma firm.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

A lawsuit seeks to block drastic cuts to Florida's ADAP program, which could strip thousands of life-saving HIV medication and insurance by March 1.

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.